# RANKL Inhibition and Breast Tissue Biomarkers

> **NCT03629717** · EARLY_PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer Prevention
- Mammographic Density

## Interventions

- **PROCEDURE:** Ultrasound-guided core needle biopsy
- **DRUG:** Denosumab
- **PROCEDURE:** Blood draw
- **DRUG:** Calcium
- **DRUG:** Vitamin D

## Key facts

- **NCT ID:** NCT03629717
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2018-12-03
- **Final completion:** 2018-12-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03629717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03629717, "RANKL Inhibition and Breast Tissue Biomarkers". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03629717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*